Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.

DCV+SOF±RBV, VEL/SOF±RBV both effective against genotypes 2, 3 hepatitis C

01 Jan 2019

Treatment regimens containing daclatasvir plus sofosbuvir with or without ribavirin (DCV+SOF±RBV) and the velpatasvir–sofosbuvir combination with or without ribavirin (VEL/SOF±RBV) deliver comparable efficacies against genotypes 2 and 3 hepatitis C virus (HCV) infection, a new study has shown.

Researchers evaluated 44 and 256 patients with genotype 2 HCV who received DVC+SOF±RBV (mean age 62.5±7.0 years 100 percent male) and VEL/SOF±RBV (mean age 63.4±6.4 years; 98.4 percent male), respectively. A total of 514 and 455 genotype 3 HCV patients were also included and were given DCV+SOF±RBV (mean age 60.9±5.6 years; 98.2 percent male) and VEL/SOF±RBV (mean age 61.0±6.7 years; 97.1 percent male), respectively.

Data for sustained virologic response (SVR) were available for 2,774 genotype 2 patients. Among these, 93.9 percent achieved SVR, the rates of which were comparable among those who were given DCV+SOF±RBV (88.1 percent) and VEL/SOF+RBV (89.5 percent; p=1.00). The use of RBV did not lead to statistical improvements in SVR rates.

In comparison, SVR was reported in 90.2 percent of 2,626 genotype 3 patients, for whom the pertinent data were available. Rates were likewise comparable between DCV+SOF±RBV (88.1 percent) and VEL/SOF±RBV (86.4 percent; p=0.51) patients.

Multivariate models showed that a decompensated disease (odds ratio [OR], 0.68; 95 percent CI, 0.47–0.99; p=0.04) and prior HCV treatment (OR, 0.51; 0.36–0.72; p<0.001) significantly reduced the likelihood of SVR in genotype 3 patients. In those with genotype 2 disease, only age <55 years exerted this effect (OR, 0.45; 0.27–0.77; p=0.002).

“The results support current evidence-based guidelines for the use of either DCV+SOF or VEL/SOF as effective treatment options for genotypes 2 and 3,” said researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.
Pearl Toh, 24 Jul 2018
SGLT-2* inhibitors and GLP-1** agonists were associated with better survival compared with DPP-4*** inhibitors or control (placebo or no treatment) in patients with type 2 diabetes (T2D) who were inadequately controlled on metformin, according to a large network meta-analysis of 236 randomized trials.